Search Results 601-610 of 17133 for treatment resistant depression
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory ...
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia · Share · Facebook · Twitter.
Division of Integrated Behavioral Health; Mayo Clinic Depression Center; Mayo Clinic John E. Herman Home and Treatment Facility; Mayo Clinic Psychiatric ...
Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...
The purpose of this study is to perform an in-depth review of pre-operative considerations and indications for spinal cord stimulation (SCS) for refractory ...
... Refractory Kidney Pain. Rochester, Minn. The purpose of this study is to examine patient reported outcomes including pain, quality of life, depression and ...
D., at Mayo Clinic studies the mechanism of action of targeted anti-cancer agents and the factors that affect tumor cell sensitivity and resistance. Most ...
Regorafenib is a type of drug called a kinase inhibitor. Regorafenib interferes with how some kinase proteins work. Some of these kinases in cancer cells might ...
Teen depression · Teen drug abuse · Nutrition and pain · Pain rehabilitation · Self-care approaches to treating pain · Treatment-resistant depression ...
This multicenter, open-label, dose-escalating study will assess the safety and efficacy of DFRF4539A in patients with relapsed or refractory multiple myeloma.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift to our 2025 Drive to Cure Cancer and transform the way cancer is treated and defeated.